The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446).
 
Bharat Burman
Employment - Janssen (I)
Stock and Other Ownership Interests - Janssen (I)
Honoraria - Medscape
 
R. Michael Tuttle
Research Funding - Elesta (Inst)
 
Ravinder K Grewal
No Relationships to Disclose
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Blueprint Medicines; Eisai; Exelixis; Lilly; UpToDate
Research Funding - HUTCHMED (Inst); Lilly (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron (Inst)
 
Shrujal S. Baxi
Employment - Flatiron Health
Stock and Other Ownership Interests - Roche
 
Laura Boucai
No Relationships to Disclose
 
Mona Sabra
No Relationships to Disclose
 
Stephanie Fish
No Relationships to Disclose
 
Keith S. Pentlow
No Relationships to Disclose
 
Sofia Haque
Honoraria - Advance Medical
Consulting or Advisory Role - Advance Medical
 
Irina Ostrovnaya
No Relationships to Disclose
 
Ronald A Ghossein
No Relationships to Disclose
 
Helen X. Chen
No Relationships to Disclose
 
John Humm
No Relationships to Disclose
 
Michael Anthony Carducci
Consulting or Advisory Role - Exelixis; Foundation Medicine; Pfizer; Roche/Genentech
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); pfizer (Inst)
 
Steven M. Larson
Stock and Other Ownership Interests - Elucida Oncology; Voreyda Theranostics; Y-mAbs Therapeutics
Patents, Royalties, Other Intellectual Property - Elucida Oncology; Samus Therapeutics; Y-mAbs Therapeutics
Other Relationship - Fonds de recherche du Quebec
(OPTIONAL) Uncompensated Relationships - Cardinal Health
 
David G. Pfister
Consulting or Advisory Role - Boehringer Ingelheim; Incyte
Research Funding - AstraZeneca (Inst); Atara Biotherapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Hookipa Pharma (Inst); Lilly (Inst); MedImmune (Inst); MeiraGTx (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
 
James A Fagin
Honoraria - Eisai Europe
Consulting or Advisory Role - Loxo
Patents, Royalties, Other Intellectual Property - 3. MSK Ref. SK 2014-024-03 Title: TREATMENT OF H-RAS-DRIVEN TUMORS. Application Number: 15/305,788.; ANTI-TSHR MULTISPECIFIC ANTIBODIES AND USES THEREOF. Provisional patent. (Inst)
 
Alan Loh Ho
Consulting or Advisory Role - AffyImmune Therapeutics; AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; Cellestia Biotech; CureVac; CureVac; Eisai; Eisai; Exelixis; Genzyme; InxMed; Kura Oncology; McGivney Global Advisors; Merck; Novartis; Prelude Therapeutics; Regeneron; Rgenta; Sanofi; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Novartis; Omniprex America
Research Funding - Allos Therapeutics; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Ayala Pharmaceuticals; Ayala Pharmaceuticals; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevar Therapeutics; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer
Travel, Accommodations, Expenses - Ayala Pharmaceuticals; Ignyta; Janssen Oncology; Klus Pharma; Kura Oncology; Kura Oncology; Kura Oncology; Merck